Carbonyl stress in schizophrenia

Area of Science:

• Neuroscience
• Biochemistry
• Genetics

Background:

• Schizophrenia is a heterogeneous disorder with complex pathophysiology.
• Idiopathic carbonyl stress has been implicated in various diseases.
• Glyoxalase I (GLO1) is a key enzyme in detoxifying reactive carbonyl species.

Purpose of the Study:

• To investigate the role of idiopathic carbonyl stress in a subpopulation of schizophrenia patients.
• To identify potential genetic factors contributing to carbonyl stress in schizophrenia.
• To explore novel therapeutic targets for treatment-resistant schizophrenia symptoms.

Main Methods:

• Identified a schizophrenia patient with a GLO1 mutation, elevated advanced glycation end-products (AGEs), and decreased vitamin B6 levels.
• Screened a larger cohort of schizophrenia patients to identify those with elevated carbonyl stress markers.
• Correlated GLO1 gene defects and AGE levels with clinical symptoms, including Positive and Negative Syndrome Scale (PANSS) scores.

Main Results:

• A subset of 20% of schizophrenia patients exhibited evidence of idiopathic carbonyl stress.
• Genetic defects in GLO1 were found to increase the risk of carbonyl stress fivefold.
• Elevated AGE levels significantly correlated with negative symptoms of schizophrenia as measured by PANSS scores.

Conclusions:

• Idiopathic carbonyl stress, particularly due to GLO1 defects, is a potential causative factor in a subset of schizophrenia.
• This finding suggests a novel pathophysiological pathway and a potential basis for schizophrenia subtype classification.
• Pyridoxamine, a vitamin B6 derivative, shows promise as a therapeutic agent for carbonyl stress-related negative symptoms in schizophrenia.